secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2024-08-23T23:59:59+00:00
Accession:  0001493152-24-033705
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte Biotechnology receives Nasdaq deficiency notice for stockholders' equity requirement
--------------------------------------------------------------------------------

- Received Notice from Nasdaq on August 19, 2024 for non-compliance with Listing Rule 5550(b)(1) requiring minimum $2,500,000 stockholders' equity.
- Company has 45 days to submit a plan to regain compliance; Nasdaq may grant up to 180-day extension.
- If plan not accepted or compliance not regained, Company can request hearing which stays suspension or delisting.
- Trading on Nasdaq continues under symbols LIXT and LIXTW with no immediate effect.
- Company intends to take reasonable measures but no assurance of regaining compliance with continued listing standards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224033705/0001493152-24-033705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224033705/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-033705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer